The economic impact of parallel imports of pharmaceuticals
The economic impact of parallel imports of pharmaceuticals
Original title: Effekten af parallelimporteret medicin
Parallel import of pharmaceuticals has taken place in Denmark and the rest of the EU since the 1970s. In 2018, parallel imports accounted for 14% of turnover in the Danish market for medicinal products. Parallel-imported pharmaceuticals are original pharmaceuticals imported from another EU/EEA country where they are cheaper than in Denmark. Hence, they are the same medicinal products as the ones the original manufacturers sell in Denmark.
Main conclusions of our study
The total savings from parallel import of pharmaceuticals in Denmark amounted to DKK 610 million in 2018
DKK 610 million corresponds to 3% of the total expenditure on pharmaceuticals in Denmark, or an average saving on parallel-imported products of 17%
Most savings occur in the primary care sector, where they amount to DKK 545 million. In the hospital sector, the corresponding savings are DKK 65 million
The study is commissioned by the Danish Association of Parallel Importers of Pharmaceuticals (Foreningen for Parallelimportører af Medicin).
contact us
Click below to read more about our Healthcare & Life Sciences service.
Related work
The European Commission
Abbott Danmark A/S
The economic impact of increased use of flash glucose monitors
Swedish Association of the Pharmaceutical Industry
The value of clinical trials in Sweden
Astellas Pharma
The Danish Radiographer Society
RT-radiographers’ role in the healthcare sector
The Danish Diabetes Association
Economic impact of sensor-based glucose monitoring of diabetes in Denmark
Ministry of Employment and Economic Affairs of Finland
Making markets work in the interest of patients
Acute Team Odense
The Suppliers of Parallel Imported Medicines in Finland
Savings from parallel import of pharmaceuticals in Finland 2016-2020
Related links
Read more on MedWatch
Read more on Svenska Dagbladet